Abeona Therapeutics Inc. announced progress in its Biologics License Application (BLA) review for prademagene zamikeracel (pz-cel), a potential treatment for recessive dystrophic epidermolysis bullosa ...
Growing body of data on PD-L1 as a cancer biomarker spurs interest Working towards partnership for non-dilutive funding of the final confirmatory head and neck cancer Registration Study VIENNA, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback